Results and insights from a phase I clinical trial of Lomecel-B for Alzheimer's disease.

Mark BrodyMarc AgroninBrad J HerskowitzSusan Y BookheimerGary W SmallBenjamin HitchinsonKevin RamdasTyler WishardKatalina Fernández McInerneyBruno VellasFelipe SierraZhijie JiangLisa Mcclain-MossCarmen PerezAna FuquaySavannah RodriguezJoshua M Hare Anthony A OlivaBernard Baumel

Published in: Alzheimer's & dementia : the journal of the Alzheimer's Association (2022)

Our results support the safety of Lomecel-B for AD, suggest clinical potential, and provide mechanistic insights. This early-stage study provides important exploratory information for larger efficacy-powered clinical trials.

Keyphrases

clinical trial
early stage
phase ii
open label
study protocol
double blind
cognitive decline
phase iii
randomized controlled trial
squamous cell carcinoma
risk assessment
mild cognitive impairment
human health
rectal cancer
locally advanced